Cerebral venous sinus thrombosis after adenovirus-vectored COVID-19 vaccination: review of the neurological-neuroradiological procedureArticle Published on 2022-05-012022-11-16 Journal: Neuroradiology [Category] 치료기술, [키워드] Ad26.COV2.S Adenovirus-vectored COVID-19 vaccination age antibody anticoagulation artefact bleeding cause cerebral cerebral venous sinus thrombosis ChAdOx1 Clinical sign complexes cortical Course COVID-19 Diagnosis diagnostic Disseminated intravascular coagulation exclusion headache heparin-induced thrombocytopenia immune increases in individual intensity Laboratory magnetic resonance imaging mandatory MRI Neurological symptoms Oxford-AstraZeneca pathogenic Platelet regimen susceptibility Symptom syndrome therapeutic therapy thrombosis thrombotic Thrombus vaccination vaccine-induced immune thrombotic thrombocytopenia venous women [DOI] 10.1007/s00234-022-02914-z PMC 바로가기
Immune complex-mediated glomerulonephritis post COVID-19 vaccination in a patient with concomitant Brucellosis브루셀라증을 동반한 환자에서 COVID-19 예방접종 후 면역복합체 매개 사구체신염Case Reports Published on 2022-05-012022-09-12 Journal: Saudi medical journal [Category] MERS, 진단, [키워드] AstraZeneca brucellosis Case report ChAdOx1 ChAdOx1 nCoV-19 chronic COVID COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccines creatinine disorder effective fibrosis flank pain Follow-up Glomerulonephritis immune ingestion initial knowledge Patient receiving renal renal insufficiency reported Safe serology therapy Treatment vaccination Vaccine Vaccines [DOI] 10.15537/smj.2022.43.5.20220139 PMC 바로가기 [Article Type] Case Reports
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccinesChAdOx1 또는 BNT162b2 백신 2회 접종 후 일반 인구에서 항체 반응 및 보호 상관 관계Article Published on 2022-05-012022-09-12 Journal: Nature Medicine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome age anti-Spike IgG antibody Antibody Response BNT162b2 BNT162b2 vaccine booster dose ChAdOx1 clinically coronavirus COVID-19 Decline dose doses General population greater IgG level Immunity individual individuals Infection intervals investigated male natural infection recipient SARS-CoV-2 second dose second vaccination significantly increased trajectory United Kingdom vaccination Vaccine vaccine dose Vaccines [DOI] 10.1038/s41591-022-01721-6 PMC 바로가기 [Article Type] Article
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant오미크론(B.1.1.529) 변이체에 대한 코로나19 백신 효과Article Published on 2022-04-212022-09-11 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 AstraZeneca B.1.1.529 B.1.617.2 BNT162b2 BNT162b2 vaccine booster booster dose booster vaccines calculated Case-control caused ChAdOx1 ChAdOx1 nCoV-19 Combination Control coronavirus coronavirus disease Coronavirus disease 2019 Course declining delta variant dose doses Effectiveness eligible England immunization investigated Moderna mRNA mRNA-1273 mRNA-1273 booster no effect of BNT162b2 omicron Omicron variant Pfizer-BioNTech Population provided rapid increase recipients security severe acute respiratory syndrome Coronavirus symptomatic disease Vaccine Vaccines variant waned [DOI] 10.1056/NEJMoa2119451 PMC 바로가기 [Article Type] Article
IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational studySARS-CoV-2 백신 접종 후 6개월까지 IgG 항체 생성 및 지속성: 북아일랜드 관찰 연구Observational Study Published on 2022-04-202022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] Adenovirus Adenovirus vector-based vaccine Anti-spike antibody Antibody Response ChAdOx1 clinically collected COVID-19 COVID-19 vaccination detectable dose evaluate first vaccination FIVE IgG antibody IgG response IgG responses individual Ireland Lateral flow device majority Oxford-AstraZeneca Oxford-AstraZeneca ChAdOx1 participant persistence plasma samples pre-vaccination Protein receive rising Sample SARS-CoV-2 second dose significantly higher Spike protein timepoint timepoints Vaccine vaccine dose [DOI] 10.1016/j.vaccine.2022.02.087 PMC 바로가기 [Article Type] Observational Study
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines불활성화 백신 2회 투여 후 성인에서 AZD1222의 저용량 대 표준 용량의 추가 용량에 대한 무작위 임상 시험Randomized Controlled Trial Published on 2022-04-202022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 95% CI Adults anti-S anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgG. Anti-spike antibody Antibody titer ARMS AstraZeneca AZD1222 baseline booster booster dose ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine completion conducted CoronaVac CoronaVac vaccine delta variant dose double-blinded enrolled evaluate Fever geometric geometric mean geometric mean ratio Geometric means GMR GMRs healthy IgG immunogenicity inactivated Inactivated vaccine Infection IQR low dose low-dose median age median interval myalgia neutralization test neutralizing antibody Neutralizing antibody titer participant Prevent Randomized randomized clinical trial randomized, controlled trial RBD IgG reactogenicity receive recipient S-RBD SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine significantly lower Standard dose surrogate surrogate virus neutralization test sVNT systemic reactogenicity the SARS-CoV-2 variant Viral Viral particles virus neutralization test wild type [DOI] 10.1016/j.vaccine.2022.03.036 PMC 바로가기 [Article Type] Randomized Controlled Trial
SARS-CoV-2 Spike Protein Expression In Vitro and Hematologic Effects in Mice Vaccinated With AZD1222 (ChAdOx1 nCoV-19)AZD1222(ChAdOx1 nCoV-19) 백신을 접종한 쥐의 시험관 내 SARS-CoV-2 스파이크 단백질 발현 및 혈액학적 효과Article Published on 2022-04-122022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] Adenovirus Adenovirus-vectored vaccine AZD1222 AZD1222 (ChAdOx1 nCoV-19) blood cell cells ChAdOx1 ChAdOx1 nCoV-19 change cleavage cleaved COVID-19 COVID-19 vaccination COVID-19 vaccine detectable Disease progression Effect Evidence expected expression hematologic hematology parameter Hematology parameters host cell host cells Host immune response host immune responses immediate effect immediate effects immune responses immunization immunohistochemistry in vitro in vivo Infection innate immune response intramuscular intravenous investigated mice morbidity morbidity and mortality nCoV neutrophil occurred parameters plasma concentration Platelet platelet activation platelet and white blood cell parameters. produced promote Protein prothrombotic state Respiratory failure response risk S1 protein S1 subunit SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike glycoprotein SARS-CoV-2 spike protein sera severe COVID-19 spike spike glycoprotein Spike protein the S1 subunit undetectable vaccination vectored vaccine vehicle Viral Viral particles White blood cell [DOI] 10.3389/fimmu.2022.836492 PMC 바로가기 [Article Type] Article
An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 감염 및 B.1.1.7 항체 및 백신 접종 상태에 따른 의료 종사자의 변이 감염 발생률에 대한 관찰 코호트 연구Observational Study Published on 2022-04-092022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종, 임상, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted age anti-spike antibodies anti-spike antibody antibody B.1.1.7 B.1.1.7 variant BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 Chain Reaction changes in confidence interval coronavirus coronavirus 2 detectable dose doses evade Evidence evidence of HCW HCWs healthcare healthcare worker Healthcare workers Immunity incidence incidence rate Infection investigated longitudinal cohort study natural natural immunity natural infection no evidence of Oxford-AstraZeneca pandemic PCR-positive Pfizer-BioNTech Poisson regression polymerase chain polymerase chain reaction provided rate ratio reduced respiratory resulting robust S-gene SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants Sequencing seronegative seropositive Seropositivity severe acute respiratory syndrome Coronavirus Sex Single-dose status symptomatic symptomatic and asymptomatic symptomatic infection United Kingdom vaccination Vaccine vaccine dose Vaccine-induced immunity whole genome Whole genome sequencing without symptom worker [DOI] 10.1093/cid/ciab608 PMC 바로가기 [Article Type] Observational Study
High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surgeDelta 변종 급증 중 의료 종사자의 무증상 감염에 대한 ChAdOx1-nCoV19 면역의 높은 실패율Article Published on 2022-04-012022-09-11 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Anti-spike Asymptomatic asymptomatic infection Breakthrough infection ChAdOx1 ChAdOx1-nCoV19 Cohort confidence confidence interval delta variant effective Effectiveness expected group healthcare healthcare worker Healthcare workers herd immunity Immunity immunization induction Infection infection rate infection rates inhibiting interval less neutralization activity outbreak Population Range reducing respiratory risk SEROLOGICAL STUDY serology Severe acute respiratory syndrome severe disease severe infections Transmission U/mL uninfected unlikely vaccination Vaccine Vaccine failure were infected wildtype [DOI] 10.1038/s41467-022-29404-3 PMC 바로가기 [Article Type] Article
Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern3가지 COVID-19 백신이 우려하는 변이체에 대해 유도된 IgG/IgA 중화 효과의 비교 분석Article Published on 2022-04-012022-09-11 Journal: The Journal of Allergy and Clinical Immunology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] (Alpha) (Beta) acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition All participants Alpha Analysis analyzed anti-SARS-CoV-2 antibody Antibody titer Antibody titers B.1.1.7 B.1.351 B.1.617.2 Beta BNT162b2 ChAdOx1 circulating variant circulating variants Comparative convalescent convalescent individual convalescent individuals convalescent patient Convalescent patients coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 convalescent patient COVID-19 convalescent patients COVID-19 vaccine Delta delta variant demonstrated E484K Efficacy heterogeneous highest IgA IgA antibodies IgA responses IgG IgG and IgA antibodies IgG response immunized in some individuals Messenger RNA mRNA mRNA-1273 mRNA-based vaccine neutralization neutralization ability neutralization capacity neutralization titer neutralize neutralizing capacity neutralizing effect of BNT162b2 patients positive Receptor binding domain recipients reported respiratory robust S1 IgG SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 WT serum serum sample serum samples severe acute respiratory syndrome Coronavirus specific antibodies Spike protein tested Vaccine Vaccines variant variants variants of concern virus Virus neutralization virus-specific antibodies was determined wild type WT virus [DOI] 10.1016/j.jaci.2022.01.013 PMC 바로가기 [Article Type] Article